Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATIC | P31939 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 16/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.50 |
| ▸ | PARP15 | Q460N3 | 5/20 | 0.50 |
| ▸ | PARP14 | Q460N5 | 4/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2346165 | 0.84 | AKR1C3 (0.51) | MEN1KMT2A | |
| Water SCHEMBL8887299 | 0.84 | AKR1C3 (0.51) | MEN1KMT2A | |
| SCHEMBL27789671 | 0.84 | MEN1 (0.54) | ATICMEN1KMT2APARP1PARP10 | |
| SCHEMBL11505875 | 0.82 | CA1 (0.49) | — | |
| SCHEMBL11335359 | 0.82 | KMT2A (0.57) | MEN1KMT2A | |
| SCHEMBL11595620 | 0.81 | L3MBTL1 (0.57) | — | |
| SCHEMBL11131080 | 0.79 | KMT2A (0.56) | MEN1KMT2A | |
| SCHEMBL9921486 | 0.79 | MEN1 (0.61) | MEN1KMT2APARP1PARP10PARP15 | |
| SCHEMBL11337097 | 0.78 | L3MBTL1 (0.48) | MEN1KMT2A | |
| SCHEMBL2475659 | 0.77 | MEN1 (0.59) | MEN1KMT2APARP1PARP10PARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072912-A1 | Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants | CEDARS-SINAI MEDICAL CENTER (US) | 2007-03-29 | — | — | US | disclosed |
| EP-1622893-A1 | NEW ALICYCLIC-AMINE-SUBSTITUTED 4-CARBOXAMIDO-BENZIMIDAZOLES AS PARP-INHIBITORS AND ANTIOXIDANTS | Hideg, Kalman (HU) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096793-A1 | NEW ALICYCLIC-AMINE-SUBSTITUTED 4-CARBOXAMIDO-BENZIMIDAZOLES AS PARP-INHIBITORS AND ANTIOXIDANTS | HIDEG KALMAN (HU) | 2004-11-11 | — | — | WO | disclosed |
| US-4258033-A | CORONARY VASODILATORS EFFECTIVE IN ISCHEMIC HEART DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072912-A1 | Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants | PARP1, PARP2, PARP11 | ATIC 256/4885MEN1 3484/4885KMT2A 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.